Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13544257 | 1.00 | KCNH2 (0.78) | KCNH2CCR5 | |
| SCHEMBL3529984 | 0.94 | KCNH2 (0.80) | KCNH2CCR5 | |
| SCHEMBL13544219 | 0.94 | KCNH2 (0.80) | KCNH2CCR5 | |
| SCHEMBL3527242 | 0.94 | KCNH2 (0.82) | KCNH2CCR5 | |
| SCHEMBL3531919 | 0.92 | KCNH2 (0.78) | KCNH2CCR5 | |
| SCHEMBL13544254 | 0.92 | KCNH2 (0.78) | KCNH2CCR5 | |
| SCHEMBL13544271 | 0.92 | KCNH2 (0.82) | KCNH2CCR5 | |
| SCHEMBL3524139 | 0.92 | KCNH2 (0.82) | KCNH2CCR5 | |
| SCHEMBL3526864 | 0.92 | KCNH2 (0.79) | KCNH2CCR5 | |
| SCHEMBL13544253 | 0.92 | KCNH2 (0.79) | KCNH2CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645771-B2 | CCR5 antagonists as therapeutic agents | SMITHKLINE BEECHAM CORP. (US) | 2010-01-12 | — | — | US | disclosed |
| US-20060229336-A1 | Ccr5 antagonists as therapeutic agents | SMITHKLINE BEECHAM CORPORATION | 2006-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229336-A1 | Ccr5 antagonists as therapeutic agents | CCR5, CCR1, CXCR3 | KCNH2 4253/4885CCR5 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.